323 related articles for article (PubMed ID: 28508306)
21. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S;
Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study.
Oddone F; Tanga L; Kóthy P; Holló G;
Adv Ther; 2020 Apr; 37(4):1436-1451. PubMed ID: 32072493
[TBL] [Abstract][Full Text] [Related]
24. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
[TBL] [Abstract][Full Text] [Related]
25. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
Javitt JC; Schiffman RM
J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373
[TBL] [Abstract][Full Text] [Related]
26. Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension.
Sharpe ED; Henry CJ; Mundorf TK; Day DG; Stewart JA; Jenkins JN; Stewart WC
Eye (Lond); 2005 Jan; 19(1):35-40. PubMed ID: 15094733
[TBL] [Abstract][Full Text] [Related]
27. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
28. Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma.
Cho SW; Kim JM; Park KH; Choi CY
Jpn J Ophthalmol; 2010 Sep; 54(5):407-13. PubMed ID: 21052902
[TBL] [Abstract][Full Text] [Related]
29. Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial.
Fechtner RD; Myers JS; Hubatsch DA; Budenz DL; DuBiner HB
Eye (Lond); 2016 Oct; 30(10):1343-1350. PubMed ID: 27367743
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma.
Kim JM; Kim TW; Park SW; Park HL; Hwang YH; Jeoung JW; Kim CY
Semin Ophthalmol; 2021 Apr; 36(3):103-109. PubMed ID: 33734910
[No Abstract] [Full Text] [Related]
31. [Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension--comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combination placebo/prostaglandins therapy].
Araie M; Yamazaki Y; Sugiyama K; Kuwayama Y; Tanihara H
Nippon Ganka Gakkai Zasshi; 2012 Oct; 116(10):955-66. PubMed ID: 23285843
[TBL] [Abstract][Full Text] [Related]
32. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol.
García-Feijoó J; Sáenz-Francés F; Martínez-de-la-Casa JM; Méndez-Hernández C; Fernández-Vidal A; Calvo-González C; García-Sánchez J
Curr Med Res Opin; 2010 Jul; 26(7):1599-606. PubMed ID: 20429818
[TBL] [Abstract][Full Text] [Related]
33. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
[TBL] [Abstract][Full Text] [Related]
34. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
Melamed S; David R
Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394
[TBL] [Abstract][Full Text] [Related]
35. Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost.
Fechtner RD; Harasymowycz P; Nixon DR; Vold SD; Zaman F; Williams JM; Hollander DA
Clin Ophthalmol; 2011; 5():945-53. PubMed ID: 21792284
[TBL] [Abstract][Full Text] [Related]
36. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy.
Konstas AG; Holló G; Haidich AB; Mikropoulos DG; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Konidaris V; Samples JR
J Ocul Pharmacol Ther; 2013 Sep; 29(7):652-7. PubMed ID: 23550916
[TBL] [Abstract][Full Text] [Related]
38. Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma.
Naito T; Okuma S; Nagayama M; Mizoue S; Ozaki M; Namiguchi K; Miyamoto K; Tanito M; Yoshikawa K
Adv Ther; 2016 Mar; 33(3):435-46. PubMed ID: 26861847
[TBL] [Abstract][Full Text] [Related]
39. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
Frampton JE
Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
[TBL] [Abstract][Full Text] [Related]
40. Additive effects of brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination in prostaglandin analog-treated Japanese glaucoma patients.
Sakata R; Mizoue S; Yoshikawa K; Adachi M; Ohkubo S; Hamada N; Naito T; Muramatsu T; Hara T; Asato R; Aihara M
Jpn J Ophthalmol; 2023 Nov; 67(6):668-677. PubMed ID: 37596444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
